AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
EVOLVE Study: The Real-life Clinical Practice With Tezepelumab in Greece
Not yet recruiting
- Conditions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 150
- Registration Number
- NCT06724575
A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults
Phase 1
Not yet recruiting
- Conditions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 105
- Registration Number
- NCT06723756
A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT06715670
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
AZD5305 hADME in Patients With Advanced Solid Malignancies
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-03
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8
- Registration Number
- NCT06713369
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2000
- Registration Number
- NCT06712563
A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab
Phase 3
Recruiting
- Conditions
- First Posted Date
- 2024-11-27
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT06706817
- Locations
- 🇪🇸
Research Site, Santiago de Compostela, Spain
A Study to Investigate Multiple Ascending Doses of AZD5004 in Healthy Japanese Participants and Participants With Type 2 Diabetes Mellitus
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-25
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT06703658
- Locations
- 🇯🇵
Research Site, Osaka-shi, Japan
A Study in Patients With Myasthenia Gravis in China
Recruiting
- Conditions
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1200
- Registration Number
- NCT06700616
- Locations
- 🇨🇳
Research Site, Beijing, China
This Project Aims to Understand the Needs of Rheumatologists and Other Specialties in the Care of Patients With SLE
Recruiting
- Conditions
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT06698900
- Locations
- 🇧🇷
Research Site, Sao Paulo, Brazil
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of AZD4144 in Participants With Severe Renal Impairment, End-stage Kidney Disease, and in Healthy Participants
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT06693765
- Locations
- 🇷🇴
Research Site, Bucuresti, Romania
© Copyright 2024. All Rights Reserved by MedPath